Table 3.
Baseline metastatic sites and R0/1/2-resection and/or local ablative therapy (LAT) rates*.
| Frequency | Resection/LAT | mOS from mCRC |
95% CI | 5-yr rate | mOS 1st resection | 95% CI | 5-yr rate | mRFS 1stR0/1-resection | 95% CI | 1-yr rate | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All metastatic sites | 1086 | 100% | 399 | 37% | 71.5 | 62·6 | 80·4 | 61% | 67·0 | 60·0 | 75·0 | 56% | 18·8 | 13·8 | 23·8 | 61% |
| One metastatic site | 586 | 100% | 309 | 53% | 74·6 | 66·0 | 83·3 | 64% | 73·0 | 64·1 | 81·8 | 60% | 18·8 | 13·1 | 24·5 | 60% |
| Liver-limited | 430 | 100% | 262 | 61% | 74·6 | 64·9 | 84·4 | 72% | 73·2 | 62·4 | 83·9 | 60% | 21·2 | 14·6 | 27·7 | 61% |
| Lung-limited | 66 | 100% | 27 | 41% | 71·8 | ·· | ·· | 74% | 70·9 | ·· | ·· | 74% | 13·0 | 6·7 | 19·3 | 56% |
| Peritoneal-limited | 45 | 100% | 11 | 24% | 61·1 | 24·9 | 97·3 | 53% | 61·1 | 23·1 | 99·0 | 53% | 14·1 | 5·4 | 22·9 | 56% |
| Other single metastasis | 45 | 100% | 9 | 20% | NE | ·· | ·· | 62% | NE | ·· | ·· | 62% | 22·3 | ·· | ·· | 63% |
| Two metastatic sites | 319 | 100% | 66 | 21% | 86·0 | 18·5 | 22·9 | 64% | 65·4 | 43·6 | 87·2 | 50% | 18·9 | 8·4 | 29·3 | 67% |
| Liver and lung | 119 | 100% | 23 | 19% | 68·9 | 53·1 | 84·8 | 80% | 65·4 | 51·8 | 79·1 | 56% | 26·8 | 17·6 | 36·1 | 78% |
| Liver and any (not lung) | 118 | 100% | 20 | 17% | 52·0 | ·· | ·· | 48% | 49·3 | ·· | ·· | 46% | 13·3 | 0·0 | 26·9 | 54% |
| Lung and any (not liver) | 31 | 100% | 2 | 6% | NE | ·· | ·· | 100% | NE | ·· | ·· | 100% | 26·4 | 16·7 | 30·1 | 80% |
| Any (not liver and not lung) | 51 | 100% | 17 | 33% | 101·3 | 20·3 | 182·3 | 58% | 97·4 | 29·3 | 165·5 | 54% | 17·6 | 11·5 | 23·7 | 69% |
| 3–6 metastatic sites | 181 | 100% | 28 | 15% | 38·6 | 31·3 | 45·8 | 32% | 31·8 | 23·9 | 39·6 | 17% | 12·7 | 2·7 | 22·8 | 58% |
| Liver, lung and any | 98 | 100% | 8 | 8% | 42·3 | 6·3 | 78·2 | 50% | 37·3 | 0·3 | 74·3 | 27% | 3·0 | ·· | ·· | 50% |
| Liver and any (not lung) | 47 | 100% | 5 | 11% | 23·1 | 13·2 | 33·1 | 20% | 22·7 | 13·5 | 31·8 | 20% | 0·7 | ·· | ·· | 50% |
| Any other (not liver) | 36 | 100% | 15 | 42% | 37·4 | 21·3 | 53·5 | 23% | 28·4 | 22·2 | 34·8 | ·· | 12·7 | 4·5 | 20·9 | 63% |
⁎
According to number and combination of metastatic sites. Median overall survival (mOS) in months and estimated 5-year OS-rate for resected patients calculated from diagnosis of metastatic disease (mOS mCRC) and from 1st resection (mOS 1st resection), and recurrence-free survival (mRFS 1st resection) and 1-year RFS-rate calculated from first resection.
mOS = median overall survival from metastatic colorectal cancer diagnosis, mOS 1st resection = median overall survival from first resection, mRFS 1st R0/1-resection = median relapse-free survival from first resection with R0/1 and/or local ablative therapy (LAT), NE = no estimate.